Impact of COVID-19 surgical delays on chronic venous disease: a multicenter observational study in France
Authors: Neaume, Nicolas; Josnin, Matthieu
Source journal: Phlebology (2026-11-16)
DOI: 10.1177/02683555261503893
Abstract
IntroductionCOVID-19 lockdowns led to widespread postponement of elective procedures, including endovenous interventions for chronic venous disease (CVD). This study aimed to evaluate the clinical impact of delayed thermal ablation in a real-world French multicenter cohort.MethodsThis prospective, multicenter observational study included 203 adults with documented great or small saphenous vein insufficiency or recurrent varicose veins whose endovenous procedures were postponed during the 2020-2021 lockdowns. Clinical severity was assessed using the Venous Clinical Severity Score (VCSS) and CEAP classification at the postponement assessment and at the rescheduling assessment. The primary analysis was performed on patients with a VCSS available at both time points. Paired t-tests and Wilcoxon signed-rank tests were used to assess within-patient change over time.ResultsAmong 203 enrolled patients, 86 (42.4%) had a VCSS available at both time points and were included in the primary analysis. The median delay between the postponement and rescheduling assessments was 80 days (IQR 69-101). Mean VCSS remained unchanged (5.4+/-3.0 vs 5.4+/-2.8; mean difference 0.0, 95% CI -0.4 to 0.4). CEAP classification was stable in 89.5% of patients, with no significant overall shift (p = 0.246). Adverse events occurred in 3.5% of cases, mainly superficial vein thrombosis. Physicians reported a negative impact of the delay in 60% of assessments, and a physician-perceived potential loss of therapeutic opportunity in 7.5% of the full cohort (n = 199) and 20.9% of the paired cohort at rescheduling (n = 86).ConclusionIn this real-world cohort, delayed endovenous treatment for CVD was not associated with clinically evident short-term deterioration in this sample. However, the high rate of missing paired data, the resulting risk of selection bias, and limited statistical power mean that a clinically relevant effect cannot be excluded. These findings suggest relative clinical stability in mild-to-moderate CVD during short-term delays, but further adequately powered studies are required.
Related topics
Related open access articles
- CHALLENGES IN THE DIAGNOSIS AND TREATMENT OF PATIENTS WITH COLORECTAL CANCER AND COVID-19 COINFECTION - CASE REPORT
- Facing COVID-19 via anti-inflammatory mechanism of action: Molecular docking and Pharmacokinetic studies of six anti-inflammatory compounds derived from Passiflora edulis
- Computational analysis by molecular docking of thirty alkaloid compounds from medicinal plants as potent inhibitors of SARS-CoV-2 main protease
- The use of non-invasive ventilation (NIV) in the treatment of patients with COVID-19
- Application of Nanotechnology in Treatment of COVID-19
- Nano Platforms in Combatting COVID-19: Unveiling Antiviral Strategies and Challenges
Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.